hotspot -WSS

hotspot

author：explore 2025-10-02 19:21:17 - browse：6375

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

WSS

Devoted Health’s losses in Medicare Advantage persist

GSK’s asthma push continues as drug succeeds in Phase 3 trials

Texas Medical Board asked to define abortion emergency exception

Updated Covid vaccine has 54% effectiveness, new study suggests

Unique patient identifier: Experts argue the benefits, pitfalls

Padmanee Sharma of MD Anderson at center of lawsuit over credit

entertainment

hotspot

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Global cancer cases to surge 77% by 2050, WHO report says

Medicare details structure of new drug price negotiation program

The Biogen Aduhelm mess could happen again

At least 13 dead in Texas as scorching temps continue

What’s missing from the debate over nursing home staff minimums

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What’s missing from the debate over nursing home staff minimums

Guidelines to prevent youth baseball injuries need more muscle

Is it ever OK for doctors to lie to their patients?

focus

Primary care doctor shortage won't be solved by free med school tuition

The effects of a landmark ruling on DNA ownership are becoming clearer

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Unique patient identifier: Experts argue the benefits, pitfalls

PBM executives asked to testify by House panel

Padmanee Sharma of MD Anderson at center of lawsuit over credit

hotspot

focus

leisure time

hotspot